Home › NDC Lookup › Ingredients › Laxative › 00283-1023-36
CEO-TWO Laxative .9 g/5.7g; .6 g/5.7g Suppository, 6 doses — NDC 00283-1023-36 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

CEO-TWO Laxative .9 g/5.7g; .6 g/5.7g Suppository, 6 doses — NDC 0283-1023-36 (Billing 00283-1023-36)

by Beutlich Pharmaceuticals, LLC · 6 DOSE PACK in 1 BOX / 5.7 g in 1 DOSE PACK

This is a package of 6 doses of CEO-TWO Laxative .9 g/5.7g; .6 g/5.7g Suppository from Beutlich Pharmaceuticals, LLC, marketed since Oct 2023 and currently FDA-listed.

NDC 00283-1023-36
🏷️ FDA NDC (as labeled) 0283-1023-36 billing pads the labeler segment with a zero
This package
Contains6 doses Pack sizes3 compare ↓
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 0283-1023-36 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0283 labeler · 1023 product · 36 package
Package marketed since
Oct 15, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
6 EA per package
Barcode (UPC-A, from the NDC)
3 0283102336 5
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0283-1023-36
Product NDC 0283-1023
11-digit billing NDC 00283102336
NCPDP billing unit EA — each (per item)
RxCUI 636185, 636188
UNII NPT6P8P3UU, 8MDF5V39QO
Application # M007
SPL Set ID 08670636-5795-4db0-e063-6294a90afa4b
Established class (EPC) Osmotic Laxative; Potassium Salt
Mechanism of action Alkalinizing Activity; Osmotic Activity
Physiologic effect Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption
Chemical class Potassium Compounds
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-10-15
Route RECTAL
Dosage form SUPPOSITORY
Substance POTASSIUM BITARTRATE; SODIUM BICARBONATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 003073
GCN 66690
HICL code 001352
Ingredient (HICL) Potassium Bitart/Sodium Bicarb
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q3
Therapeutic class — intermediate (HIC2) Anal-Rectal Preparations
HIC3 code Q3S
Therapeutic class — specific (HIC3) Laxatives, Local/Rectal
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name CEO-TWO 0.9-0.6 GM SUPPOSITORY
FDB brand name Ceo-Two
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 003073
  • GCN: 66690
  • HICL (First Databank): 001352
  • AHFS class code: 56:12.00.00
  • RxCUI (RxNorm): 636185
Why two NDCs? The FDA registers this code as 0283-1023-36 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00283-1023-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CEO-TWO 0.9-0.6 GM SUPPOSITORY Ingredient Potassium Bitart/Sodium Bicarb
🧪 What is this product?

CEO-TWO is an over-the-counter laxative suppository inserted rectally. It contains potassium bitartrate and sodium bicarbonate, which are typically used together to produce carbon dioxide gas in the colon. This gas helps stimulate bowel movement and is commonly used as a laxative to provide relief from occasional constipation.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 2 doses 54 doses
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00283-1023-02 0283-1023-02 Main listing 2 DOSE PACK in 1 BOX / 5.7 g in 1 DOSE PACK 2023-10-15 — Active
00283-1023-36 You're viewing this 6 DOSE PACK in 1 BOX / 5.7 g in 1 DOSE PACK 2023-10-15 — Active
00283-1023-54 0283-1023-54 54 DOSE PACK in 1 BOX / 5.7 g in 1 DOSE PACK 2023-10-15 — Active

Pack size FAQ

What quantity is in this package?
This package contains 6 doses — 6 dose pack in 1 box / 5.7 g in 1 dose pack.
How does this package differ from NDC 00283-1023-02?
Both are CEO-TWO Laxative .9 g/5.7g; .6 g/5.7g Suppository — the drug itself is identical. This page's package is the 6 doses one, while NDC 00283-1023-02 is the 2 doses package.
What NDC number is used to bill for this package of CEO-TWO Laxative .9 g/5.7g; .6 g/5.7g Suppository?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ceo-Two .9 g/5.7g; .6 g/5.7gthis 00283-1023-36 Beutlich 6 doses — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Oct 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeBullet
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBeutlich Pharmaceuticals, LLC
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code00283
First marketedOct 2023
Product typeHuman Otc Drug
Portfolio16 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 18 words ▾

Uses for relief of occasional constipation this product generally produces a bowel movement in 5 to 30 minutes

⏱️ Dosage and Administration 98 words ▾

Directions Adults and children 12 years of age and over: rectal dosage is one suppository containing 0.6 gram of sodium bicarbonate and 0.9 gram of potassium bitartrate in a single daily dose Children under 12 years of age: consult a doctor Detach one suppository from the strip; remove plastic wrapper. Moisten suppository by placing it under a water tap for 30 seconds, or in a cup of water for at least 10 seconds, before insertion. Insert rectally, bulb shape first, past largest diameter of suppository.

Retain suppository as long as possible (usually 10 to 30 minutes) before defecating.

⚠️ Warnings 5 words ▾

Warnings For rectal use only

📦 Storage and Handling 45 words ▾

Other information store at 20-25 ºC (68-77 ºF). Do not exceed 30 ºC (86 ºF). do not refrigerate for your protection, suppositories are individually wrapped in tamper-resistant film. Do not use if film is torn or open when purchased. save this carton for future reference

🧪 Active Ingredient 10 words ▾

Active ingredients Potassium bitartrate, 0.9 g Sodium bicarbonate, 0.6 g

🧪 Inactive Ingredients 4 words ▾

Inactive ingredient polyethylene glycol

🎯 Purpose 2 words ▾

Purposes Laxative

💬 Information for Patients 6 words ▾

each suppository contains: sodium, 164 mg

📄 Do Not Use 48 words ▾

Do not use laxative products when abdominal pain, nausea, or vomiting are present unless directed by a doctor Do not use this product if you are on a low salt diet unless directed by a doctor Do not lubricate with mineral oil or petrolatum prior to rectal insertion

📄 Ask a Doctor Before Use If 43 words ▾

If you have noticed a sudden change in bowel habits that persists over a period of 2 weeks, consult a doctor before using a laxative Laxative products should not be used for a period longer than 1 week unless directed by a doctor

📄 Stop Use and Ask a Doctor If 25 words ▾

Rectal bleeding or failure to have a bowel movement after use of a laxative may indicate a serious condition. Discontinue use and consult your doctor.

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding ask a health professional before use

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children If swallowed, get medical help or contact a poison control center right away

📄 Questions or Comments 11 words ▾

Questions or comments? 1-800-238-8542 M-F: 8:00 a.m. - 4:30 p.m. ET

📄 Package Label / Principal Display Panel 24 words ▾

Prinicipal Display Panel - 54 count CEO-TWO Laxative Suppositories Box of 2: Box of 6: Box of 54: 2-count box 6-count box 54-count box

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Beutlich Pharmaceuticals, LLC. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 2 doses (00283-1023-02), 54 doses (00283-1023-54). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Beutlich Pharmaceuticals, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.